Overview

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Status:
Not yet recruiting

Trial end date:
2028-04-30

Target enrollment:

Participant gender:

Summary

Flumatinib is an orally available TKI with high selectivity and potency against BCR-ABL1 kinase. It's a multi-center, open-label, real world study to explore the efficacy and safety of Flumatinib versus Imatinib as the first line therapy in patients with chronic myleiod leukemia(CML) in chronic phase(CP).

Phase:

Phase 4

Details

Lead Sponsor:

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Treatments:

HH-GV-678
Imatinib Mesylate